SynthesisJournal of health, population, and nutrition2025
The effect of barberry supplementation on components of metabolic syndrome: a grade assessment systematic review and meta-analysis of randomized controlled trials.
Synthesis in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolyphenol-rich foods, such as barberry, improve cardiovascular risk factors, but evidence remains inconsistent. Therefore, this systematic review and meta-analysis were carried out to assess the effects of barberry supplementation on components of metabolic syndrome in adults.
methodA comprehensive literature search of Web of Science, Embase, PubMed, Scopus, and the Cochrane Library was conducted up to July 2025. We included randomized clinical trials that examined the effect of barberry on one of the components of metabolic syndrome in this meta-analysis. Weighted mean differences (WMD) were pooled using a random-effects model.
resultsEleven studies published between 2012 and 2023 were included, comprising 718 participants. Barberry supplementation significantly reduced weight (WMD = - 1.48 kg; 95% CI: - 2.94 to - 0.02), systolic blood pressure (WMD: - 9.84; 95% CI: - 17.36 to - 2.31), diastolic blood pressure (WMD: - 11.31; 95% CI: - 19.63 to - 3.00), total cholesterol (WMD = - 17.90 mg/dL; 95% CI: - 32.99 to - 2.81), low-density lipoprotein cholesterol (WMD = - 11.38 mg/dL; 95% CI: - 21.35 to - 1.40), and triglyceride (WMD = - 23.63 mg/dL; 95% CI: - 35.58 to - 11.68), FBS (WMD = - 16.69 mg/dL; 95% CI: - 30.46 to - 2.93), HOMA-IR (WMD = - 0.95; 95% CI: - 1.79 to - 0.12), insulin (WMD = - 1.70 mU/L; 95% CI: - 2.33 to - 1.08). It also increased high-density lipoprotein cholesterol levels (WMD = 2.46 mg/dL; 95% CI: 0.61 to 4.31). However, no significant effect was found for glycated hemoglobin (WMD = - 0.72%; 95% CI: - 1.85 to 0.40) or body mass index (WMD = - 0.28 kg/m
conclusionBarberry supplementation elicits modest but significant improvements in key components of metabolic syndrome, including blood pressure, weight, lipid profile, and glycemic indices. These results support its potential as an adjunctive dietary intervention for managing metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.